{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:19:24Z","timestamp":1788311964709,"version":"build-2803163510"},"reference-count":58,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Global health emergencies consistently expose and exacerbate vaccine inequities, with high-income countries prioritising their populations and leaving low- and middle-income countries (LMICs) facing delays and shortages. Diseases primarily affecting LMICs receive limited attention from global vaccine developers because of perceived low market value and limited financial return, further entrenching these disparities. Africa\u2019s limited investment in vaccine manufacturing has heightened its vulnerability during outbreaks, including yellow fever, Ebola, meningococcal meningitis, mpox, and most recently, coronavirus disease 2019 (COVID-19).\nAim:\u00a0This study examines the barriers to vaccine equity in Africa and critically analyses Nigeria\u2019s post-COVID-19 efforts to establish a viable, local vaccine manufacturing ecosystem.\nSetting:\u00a0The research focuses on Nigeria within the broader African vaccine manufacturing landscape, using it as a case study to explore both national and continental dynamics.\nMethods:\u00a0The study draws on document analysis of strategic plans, regulatory reports, and partnership announcements, complemented by qualitative insights from key informant interviews with stakeholders involved in vaccine policy, regulation, and production in Nigeria and across West Africa.\nResults:\u00a0Post-pandemic momentum has catalysed significant shifts: Nigeria has developed a national vaccine manufacturing strategy and secured international partnerships and financing commitments. The regulatory authority, National Agency for Food and Drug Administration and Control (NAFDAC), achieved the World Health Organization (WHO) Maturity Level 3 status, marking critical progress. Nonetheless, persistent gaps remain in research and development capacity, workforce development, regulatory agility, and infrastructure readiness.\nConclusion:\u00a0While Nigeria has made notable progress since the COVID-19 pandemic, sustainable vaccine manufacturing requires long-term investment in research and development, policy reform, skills development, and regional cooperation. Failure to address these challenges systematically risks undermining current gains.\nContribution:\u00a0This article provides insights to support ongoing and future investments in Nigeria\u2019s vaccine manufacturing sector, guiding government policy, international partnerships, and potential investors.<\/jats:p>","DOI":"10.4102\/jphia.v17i1.1560","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:24:48Z","timestamp":1769783088000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nigeria\u2019s post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications"],"prefix":"10.4102","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2435","authenticated-orcid":false,"given":"Oyeronke","family":"Oyebanji","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00a0jsq62","id-type":"ROR","asserted-by":"publisher"}],"name":"London School of Hygiene & Tropical Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0742-2299","authenticated-orcid":false,"given":"Olufunke","family":"Falade","sequence":"additional","affiliation":[{"name":"Nigeria Presidential Unlocking Healthcare Value Chain, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8524-5358","authenticated-orcid":false,"given":"Frederik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Regional Vaccine Manufacturing Collaborative, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-0304","authenticated-orcid":false,"given":"David","family":"Heymann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00a0jsq62","id-type":"ROR","asserted-by":"publisher"}],"name":"London School of Hygiene & Tropical Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-4709","authenticated-orcid":false,"given":"Beate","family":"Kampmann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00a0jsq62","id-type":"ROR","asserted-by":"publisher"}],"name":"London School of Hygiene & Tropical Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Gleeson D, Townsend B, Tenni BF, Phillips T. Global inequities in access to COVID-19 health products and technologies: A political economy analysis. Health Place. 2023;83:103051. https:\/\/doi.org\/10.1016\/j.healthplace.2023.103051","DOI":"10.1016\/j.healthplace.2023.103051"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mammen M, Narasimhan V, Kuntz R, Lewis-Hall F, Poul M, Schechter A. Health product manufacturers and innovators COVID-19 impact assessment: Lessons learned and compelling needs. NAM Perspect. 2022;2022:10.31478\/202201b. https:\/\/doi.org\/10.31478\/202201b","DOI":"10.31478\/202201b"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Luyckx VA. Health inequality and inequity during the COVID-19 pandemic. Nephrol Dial Transplant. 2023;38(11):2417\u20132419. https:\/\/doi.org\/10.1093\/ndt\/gfad119","DOI":"10.1093\/ndt\/gfad119"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Panwar R, Pinkse J, De Marchi V. The future of global supply chains in a post-COVID-19 world. Calif Mgmt Rev. 2022;64(2):5\u201323. https:\/\/doi.org\/10.1177\/00081256211073355","DOI":"10.1177\/00081256211073355"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"De Marchi V, Alford M. State policies and upgrading in global value chains: A systematic literature review. J Int Bus Policy. 2022;5(1):88\u2013111. https:\/\/doi.org\/10.1057\/s42214-021-00107-8","DOI":"10.1057\/s42214-021-00107-8"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Koller CN, Schwerzmann CJ, Suzanne A, et al. Addressing different needs: The challenges faced by india as the largest vaccine manufacturer while conducting the world\u2019s biggest COVID-19 vaccination campaign. Epidemiol. 2021;2(3):454\u2013470. https:\/\/doi.org\/10.3390\/epidemiologia2030032","DOI":"10.3390\/epidemiologia2030032"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dzau VJ, Balatbat CA, Offodile AC. Closing the global vaccine equity gap: Equitably distributed manufacturing. Lancet. 2022;399(10339):1924\u20131926. https:\/\/doi.org\/10.1016\/S0140-6736(22)00793-0","DOI":"10.1016\/S0140-6736(22)00793-0"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sell TK, Gastfriend D, Watson M, et al. Building the global vaccine manufacturing capacity needed to respond to pandemics. Vaccine. 2021;39(12): 1667. https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.017","DOI":"10.1016\/j.vaccine.2021.02.017"},{"key":"ref8","unstructured":"Gostin LO, Jha AK, Finch A. The Mpox global health emergency \u2013 A time for solidarity and equity. N Engl J Med [serial online]. 2024 [cited 2024 Oct 03]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMp2410395"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ferranna M. Causes and costs of global COVID-19 vaccine inequity. Semin Immunopathol. 2023; 45(4\u20136):469\u2013480. https:\/\/doi.org\/10.1007\/s00281-023-00998-0","DOI":"10.1007\/s00281-023-00998-0"},{"key":"ref10","unstructured":"Vaccine doses allocated to 9 African countries hardest hit by mpox surge [homepage on the Internet]. [cited 2024 Nov 08]. Available from: https:\/\/www.who.int\/news\/item\/06-11-2024-vaccine-doses-allocated-to-9-african-countries-hardest-hit-by-mpox-surge"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hayman B, Suri RK. Sustainable vaccine manufacturing in low- and middle-Income countries. Vaccine. 2022;40(50):7288\u20137304. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.044","DOI":"10.1016\/j.vaccine.2022.10.044"},{"key":"ref12","unstructured":"Smith DRM, Turner J, Fahr P, et al. Health and economic impacts of Lassa vaccination campaigns in West Africa. Nat Med 2024 [serial online]. 2024 [cited 2024 Oct 13];1\u201310. Available from: https:\/\/www.nature.com\/articles\/s41591-024-03232-y"},{"key":"ref13","unstructured":"Africa Centres for Disease Control and Prevention (Africa CDC). Partnerships for African Vaccine Manufacturing (PAVM): Framework for action [homepage on the Internet]. Addis Ababa: Africa CDC; 2022 [cited 2025 Jan 25]. Available from: https:\/\/africacdc.org\/download\/partnerships-for-african-vaccine-manufacturing-pavm-framework-for-action\/"},{"key":"ref14","unstructured":"Africa Centres for Disease Control and Prevention (Africa CDC). The change in African vaccine manufacturing landscape [homepage on the Internet]. 2024 [cited 2025 Feb 16]. Available from: https:\/\/africacdc.org\/wp-content\/uploads\/2024\/11\/The-change-in-African-vaccine-manufacturing-landscape-.pdf"},{"key":"ref15","unstructured":"PATH. How has the African vaccine manufacturing landscape changed in the last year? [homepage on the Internet]. PATH; 2024 [cited 2024 Nov 13]. Available from: https:\/\/www.path.org\/our-impact\/articles\/how-has-the-african-vaccine-manufacturing-landscape-changed-in-the-last-year\/"},{"key":"ref16","unstructured":"World Health Organization. A global strategy to eliminate yellow fever epidemics 2017\u20132026 [homepage on the Internet]. 2018 [cited 2025 Feb 16]. Available from: www.who.int\/csr\/disease\/yellowfev\/eye-strategy\/en\/"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kraemer MUG, Faria NR, Reiner RC, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015\u201316: A modelling study. Lancet Infect Dis. 2017;17(3):330\u2013338. https:\/\/doi.org\/10.1016\/S1473-3099(16)30513-8","DOI":"10.1016\/S1473-3099(16)30513-8"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Barrett ADT. Yellow fever in angola and beyond \u2013 The problem of vaccine supply and demand. N Engl J Med. 2016;375(4):301\u2013303. https:\/\/doi.org\/10.1056\/NEJMp1606997","DOI":"10.1056\/NEJMp1606997"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Monath TP, Woodall JP, Gubler DJ, et al. Yellow fever vaccine supply: A possible solution. Lancet. 2016;387(10028):1599\u20131600. https:\/\/doi.org\/10.1016\/S0140-6736(16)30195-7","DOI":"10.1016\/S0140-6736(16)30195-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lindsey NP, Horton J, Barrett ADT, et al. Yellow fever resurgence: An avoidable crisis? NPJ Vaccines. 2022;7(1):137. https:\/\/doi.org\/10.1038\/s41541-022-00552-3","DOI":"10.1038\/s41541-022-00552-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Badio M, Lhomme E, Kieh M, et al. Partnership for Research on Ebola VACcination (PREVAC): Protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials. 2021;22(1):1\u201315. https:\/\/doi.org\/10.1186\/s13063-021-05572-3","DOI":"10.1186\/s13063-021-05572-3"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ohimain EI, Silas-Olu D. The 2013\u20132016 Ebola virus disease outbreak in West Africa. Curr Opin Pharmacol. 2021;60:360\u2013365. https:\/\/doi.org\/10.1016\/j.coph.2021.08.002","DOI":"10.1016\/j.coph.2021.08.002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Gouglas D, Christodoulou M, Plotkin SA, Hatchett R. Cepi: Driving progress toward epidemic preparedness and response. Epidemiol Rev. 2019;41(1):28\u201333.","DOI":"10.1093\/epirev\/mxz012"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ropero-\u00c1lvarez AM, Whittembury A, Kurtis HJ, Dos Santos T, Danovaro-Holliday MC, Ruiz-Matus C. Pandemic influenza vaccination: Lessons learned from Latin America and the Caribbean. Vaccine. 2012 Jan 20;30(5):916\u2013921. https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.092","DOI":"10.1016\/j.vaccine.2011.11.092"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Fidler DP. Negotiating equitable access to influenza vaccines: Global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. PLoS Med. 2010;7(5):e1000247. https:\/\/doi.org\/10.1371\/journal.pmed.1000247","DOI":"10.1371\/journal.pmed.1000247"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ojiako CP. Innovative health financing mechanisms: The case of Africa\u2019s unified approach to vaccine acquisition. Health Policy Plan. 2024;39(1):84. https:\/\/doi.org\/10.1093\/heapol\/czad109","DOI":"10.1093\/heapol\/czad109"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Nhamo G, Chikodzi D, Kunene HP, Mashula N. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs. Glob Public Health. 2021;16(3):319\u2013339. https:\/\/doi.org\/10.1080\/17441692.2020.1860249","DOI":"10.1080\/17441692.2020.1860249"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Kunyenje CA, Chirwa GC, Mboma SM, et al. COVID-19 vaccine inequity in African low-income countries. Front Public Health. 2023;11:1087662. https:\/\/doi.org\/10.3389\/fpubh.2023.1087662","DOI":"10.3389\/fpubh.2023.1087662"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kaddar M, Saxenian H, Senouci K, Mohsni E, Sadr-Azodi N. Vaccine procurement in the Middle East and North Africa region: Challenges and ways of improving program efficiency and fiscal space. Vaccine. 2019;37(27):3520\u20133528. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.029","DOI":"10.1016\/j.vaccine.2019.04.029"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Apeagyei AE, Lidral-Porter B, Patel N, et al. Financing health in sub-Saharan Africa 1990\u20132050: Donor dependence and expected domestic health spending. PLoS Glob Public Health. 2024;4(8):e0003433. https:\/\/doi.org\/10.1371\/journal.pgph.0003433","DOI":"10.1371\/journal.pgph.0003433"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nonvignon J, Soucat A, Ofori-Adu P, Adeyi O. Making development assistance work for Africa: From aid-dependent disease control to the new public health order. Health Policy Plan. 2024;39(Suppl 1):i79. https:\/\/doi.org\/10.1093\/heapol\/czad092","DOI":"10.1093\/heapol\/czad092"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Thomson M, Kentikelenis A, Stubbs T. Structural adjustment programmes adversely affect vulnerable populations: A systematic-narrative review of their effect on child and maternal health. Public Health Rev. 2017;38(1):1\u201318. https:\/\/doi.org\/10.1186\/s40985-017-0059-2","DOI":"10.1186\/s40985-017-0059-2"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Muckstadt JA, Klein MG, Jackson PL, Gougelet RM, Hupert N. Efficient and effective large-scale vaccine distribution. Int J Prod Econ. 2023;262:108921. https:\/\/doi.org\/10.1016\/j.ijpe.2023.108921","DOI":"10.1016\/j.ijpe.2023.108921"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Nomhwange T, Jean Baptiste AE, Ezebilo O, et al. The resurgence of yellow fever outbreaks in Nigeria: A 2-year review 2017\u20132019. BMC Infect Dis. 2021;21(1): 1054. https:\/\/doi.org\/10.1186\/s12879-021-06727-y","DOI":"10.1186\/s12879-021-06727-y"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: A snapshot. PLoS Pathog. 2021;17(12):e1010078. https:\/\/doi.org\/10.1371\/journal.ppat.1010078","DOI":"10.1371\/journal.ppat.1010078"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Emanuel EJ, Buchanan A, Chan SY, et al. What are the obligations of pharmaceutical companies in a global health emergency? Lancet (London, England). 2021;398(10304): 1015. https:\/\/doi.org\/10.1016\/S0140-6736(21)01378-7","DOI":"10.1016\/S0140-6736(21)01378-7"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Noor MN, Rahman-Shepherd A, Siddiqui AR, et al. Socioecological factors linked with pharmaceutical incentive-driven prescribing in Pakistan. BMJ Glob Health. 2021;6(Suppl 3):10853. https:\/\/doi.org\/10.1136\/bmjgh-2022-010853","DOI":"10.1136\/bmjgh-2022-010853"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Paremoer L, Pollock A. \u2018A passion to change the landscape and drive a renaissance\u2019: The mRNA Hub at Afrigen as decolonial aspiration. Front Public Health. 2022;10:1065993. https:\/\/doi.org\/10.3389\/fpubh.2022.1065993","DOI":"10.3389\/fpubh.2022.1065993"},{"key":"ref39","unstructured":"Gavi. African Vaccine Manufacturing Accelerator (AVMA) [homepage on the Internet]. [cited 2024 Jun 25]. Available from: https:\/\/www.gavi.org\/programmes-impact\/types-support\/regional-manufacturing-strategy\/avma"},{"key":"ref40","unstructured":"European Commission. EU support for COVID-19 vaccine manufacturing in Senegal [homepage on the Internet]. European Commission; 2021 [cited 2024 Jan 28]. Available from: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_3562"},{"key":"ref41","unstructured":"Seymour S. South Africa: EIB to support increased vaccine production by Biovac [homepage on the Internet]. European Investment Bank; 2022 [cited 2024 Jan 28]. Available from: https:\/\/www.eib.org\/en\/press\/all\/2022-263-eib-to-support-increased-vaccine-production-in-south-africa-by-biovac"},{"key":"ref42","unstructured":"African drugmaker Aspen in talks to manufacture mpox vaccines [homepage on the Internet]. Reuters; [cited 2024 Oct 06]. Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/african-drugmaker-aspen-advanced-talks-manufacture-mpox-vaccines-2024-09-03\/"},{"key":"ref43","unstructured":"Health Policy Watch. Despite hosting MRNA hub, south africa buys vaccines from India \u2013 Highlighting tension between price pressures and local production [homepage on the Internet]. Health Policy Watch; 2023 [cited 2024 Nov 16]. Available from: https:\/\/healthpolicy-watch.news\/despite-hosting-mrna-hub-south-africa-buys-vaccines-from-india-highlighting-tension-between-price-and-local-production\/"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Saied AA, Metwally AA, Dhawan M, Choudhary OP, Aiash H. Strengthening vaccines and medicines manufacturing capabilities in Africa: Challenges and perspectives. EMBO Mol Med. 2022;14(8):e16287. https:\/\/doi.org\/10.15252\/emmm.202216287","DOI":"10.15252\/emmm.202216287"},{"key":"ref45","unstructured":"Egypt opens hepatitis B and pentavalent vaccine production line \u2013 Health \u2013 Egypt \u2013 Ahram Online [homepage on the Internet]. [cited 2024 Oct 6]. Available from: https:\/\/english.ahram.org.eg\/NewsContent\/1\/1236\/492405\/Egypt\/Health\/Egypt-opens-hepatitis-B-and-pentavalent-vaccine-pr.aspx"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Abubakar I, Dalglish SL, Angell B, et al. The Lancet Nigeria Commission: Investing in health and the future of the nation. Lancet. 2022;399(10330):1155\u20131200. https:\/\/doi.org\/10.1016\/S0140-6736(21)02488-0","DOI":"10.1016\/S0140-6736(21)02488-0"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Owolade AJJ, Sokunbi TO, Aremu FO, et al. Strengthening Africa\u2019s capacity for vaccine research: Needs and challenges. Health Promot Perspect. 2022;12(3):282\u2013285. https:\/\/doi.org\/10.34172\/hpp.2022.36","DOI":"10.34172\/hpp.2022.36"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Akegbe H, Onyeaka H, Michael Mazi I, et al. The need for Africa to develop capacity for vaccinology as a means of curbing antimicrobial resistance. Vaccine X. 2023;14:100320. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100320","DOI":"10.1016\/j.jvacx.2023.100320"},{"key":"ref49","unstructured":"Eigbike M. Health research capacity strengthening in low- and middle-income countries: Current situation and opportunities to leverage data for better coordination and greater impact [homepage on the Internet]. 2020 [cited 2025 Mar 18]. Available from: https:\/\/tdr.who.int\/docs\/librariesprovider10\/essence\/essence-mechanism-consultant-report-2020.pdf"},{"key":"ref50","unstructured":"Nigeria Institute for Pharmaceutical Research and Development. National plan for vaccine research and development and local production. Abuja: Nigeria Institute for Pharmaceutical Research and Development; 2023. Unpublished report."},{"key":"ref51","unstructured":"Punch Newspaper. FG to crash drug prices, gets $1bn from AfreximBank [homepage on the Internet]. 2024 [cited 2024 Mar 23]. Available from: https:\/\/punchng.com\/fg-to-crash-drug-prices-gets-1bn-from-afreximbank\/"},{"key":"ref52","unstructured":"European Commission. EU and Nigeria boost cooperation on research and learning mobility [homepage on the Internet]. EEAS; 2024 [cited 2024 Aug 04]. Available from: https:\/\/www.eeas.europa.eu\/delegations\/nigeria\/eu-and-nigeria-boost-cooperation-research-and-learning-mobility_en?s=114"},{"key":"ref53","unstructured":"Wellcome Trust, Biovac, Boston Consulting Group(BCG). Scaling Up African vaccine manufacturing Capacity Perspectives from the African vaccine-manufacturing industry on the challenges and the need for support. 2023."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Kumraj G, Pathak S, Shah S, et al. Capacity building for vaccine manufacturing across developing countries: The way forward. Hum Vaccin Immunother. 2022;18(1):1\u201317. https:\/\/doi.org\/10.1080\/21645515.2021.2020529","DOI":"10.1080\/21645515.2021.2020529"},{"key":"ref55","unstructured":"WHO Team, Local Production and Assistance (LPA), World Health Organization. A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals: The Nigeria context [homepage on the Internet]. Geneva: World Health Organization; 2024 [cited 2025 Feb 16]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240092761"},{"key":"ref56","unstructured":"Tekki IS, Nwosu C, Okewole PA. Challenges and prospects of anti-rabies vaccines production in Nigeria. J Vaccines Vaccin [homepage on the Internet]. 2013 [cited 2025 Feb 11];4(8):212. Available from: https:\/\/www.walshmedicalmedia.com\/open-access\/challenges-and-prospects-of-anti-rabies-vaccines-production-in-nigeria-2157-7560.1000212.pdf"},{"key":"ref57","unstructured":"World Economic Forum. Regionalized vaccine manufacturing collaborative: a framework for enhancing vaccine access through regionalized manufacturing ecosystems [homepage on the Internet]. 2024 [cited 2025 Feb 19]. Available from: https:\/\/www3.weforum.org\/docs\/WEF_Regionalized_Vaccine_Manufacturing_Collaborative_2024.pdf"}],"container-title":["Journal of Public Health in Africa"],"original-title":[],"link":[{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1560\/2713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:24:54Z","timestamp":1769783094000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/jphia.v17i1.1560","relation":{},"ISSN":["2038-9922","2038-9930"],"issn-type":[{"value":"2038-9922","type":"print"},{"value":"2038-9930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"a1560"}}